Dr. Ray Goodrich’s research program is focused on using new methods to stimulate immune response in patients with cancer and to prevent infectious diseases. His lab developed Innocell, a new treatment for patients with advanced stage ovarian cancer. In addition, his group is developing methods (SolaVAX) to generate new vaccine candidates for infectious diseases including COVID and Influenza. Goodrich served as the Executive Director of the Infectious Disease Research Center from 2016 to 2023. He spent 30 years in the private sector, leading research groups in the development of medical devices and products. Goodrich is the recipient of an honorary Order of Military Medical Merit (2018) and the CSU award for Innovative Excellence (2021). He is a member of the HHS Advisory Committee on Blood and Tissue Safety and Availability, the advisory board for the School of Biomedical Engineering, and is a member of the Board of Directors of the Association for the Advancement of Blood and Biotherapies.
View the complete up-to-date list on Google Patents.
